All the Active Ingredient Drugs
Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml. PRE-FILL. PENS: 5. Init. 0.6 mg dly.
Dose should be incr. to 3.0 mg dly. in
increm. of 0.6 mg with at least one wk.
interv. to improve GI tolerabil. If escal.
to the next dose step is not tolerated
for two consec. wks., consider discont.
tmt. Dly. doses higher than 3.0 mg are
not recomm.
Adults: as adjunct to reduc. cal. diet and
incr. phys. act. for wt. managt. in pts. BMI
30 (obes.), or 27 to < 30 (overwt.) and at
least one comorbidity such as
dysglycaemia (pre-diabet. or type 2
diabet. Mellit.), hypertens., or
dyslipidaemia and who failed wt.
managt. intervent. Tmt. should be
discont. aft. 12 wks. on the 3 mg/day
dose if pts. have not lost at least 5% of
their initial BW. Adolescents (>12 years)
as an adjunct to a healthy nutr. and incr.
phys. act. for wt. managt. in pts. with
BMI=30. Tmt. should be discont. and
re-eval. if pts. have not lost at least 4% of
their BMI or BMI z score after 12 weeks on
the 3 mg/day or max. toler. dose. Re-eval.
should be perf. periodic.
C/I: Hypersens.
Insulin. Insulin Degludec 100 U/ml, Liraglutide 3.6 mg /ml. PRE-FILL. PEN: 1×3 mL (eq.to Insulin
Degludec 300 UN + Liraglutide 10.8
mg). The drug admin. as dose steps. Add-on to oral glucose-low. med. products Init. dose is 10 dose steps (10 units insulin degludec and 0.36 mg liraglutide). One dose step cont. 1 UN of insulin degludec and 0.036 mg of liraglutide. The max. dly. dose is 50 dose steps (50 UN insulin degludec and 1.8 mg liraglutide). The dose counter on the pen shows the number of dose steps. Dosage must be ajust. individ.
Tmt. of adult. with type 2 diab. mell. to improve glycaem. control in comb. with oral glucose-low. med. products when these alone or comb. with a GLP-1 receptor ag. or basal insulin do not provide adeq. glycaemic control
C/I: Hypersens.
